Top

Published in:

Open Access 01-12-2024 | Research

Identification of stemness-related glycosylation changes in head and neck squamous cell carcinoma

Authors: E Routila, R Mahran, S Salminen, H Irjala, E Haapio, E Kytö, S Ventelä, K Petterson, J Routila, K Gidwani, J Leivo

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Altered glycosylation is a hallmark of cancer associated with therapy resistance and tumor behavior. In this study, we investigated the glycosylation profile of stemness-related proteins OCT4, CIP2A, MET, and LIMA1 in HNSCC tumors.

Methods

Tumor, adjacent normal tissue, and blood samples of 25 patients were collected together with clinical details. After tissue processing, lectin-based glycovariant screens were performed.

Results

Strong correlation between glycosylation profiles of all four stemness-related proteins was observed in tumor tissue, whereas glycosylation in tumor tissue, adjacent normal tissue, and serum was differential.

Conclusions

A mannose- and galactose-rich glycosylation niche associated with stemness-related proteins was identified.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed

Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233:780–6. https://doi.org/10.1038/s41415-022-5166-x.CrossRefPubMedPubMedCentral

Denissoff A, Huusko T, Ventelä S, Niemelä S, Routila J. Exposure to alcohol and overall survival in head and neck cancer: a regional cohort study. Head \& Neck. 2022. https://doi.org/10.1002/hed.27125.;n/a n/a.CrossRef

Ventelä S, Sittig E, Mannermaa L, Mäkelä J-A, Kulmala J, Löyttyniemi E, et al. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance. Oncotarget. 2015;6:144–58. https://doi.org/10.18632/oncotarget.2670.CrossRefPubMed

Routila J, Suvila K, Grénman R, Leivo I, Westermarck J, Ventelä S. Cancer cell line microarray as a novel screening method for identification of radioresistance biomarkers in head and neck squamous cell carcinoma. BMC Cancer. 2021;21:868.CrossRefPubMedPubMedCentral

Khan M, Khaznadar SS, Routila J, Ventelä S, Schmid E, Gebhart B et al. Hepatocyte growth factor receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients. Head Neck. 2020;42.

Lüttich L, Besso MJ, Heiden S, Koi L, Baumann M, Krause M et al. Tyrosine kinase c-MET as therapeutic target for Radiosensitization of Head and Neck squamous cell carcinomas. Cancers (Basel). 2021;13.

Routila J, Qiao X, Weltner J, Rantala JK, Carpén T, Hagström J, et al. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Oral Oncol. 2022;127:105772.CrossRefPubMed

Harada K, Ferdous T, Cui D, Kuramitsu Y, Matsumoto T, Ikeda E, et al. Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors. BMC Cancer. 2016;16:548. https://doi.org/10.1186/s12885-016-2416-9.CrossRefPubMedPubMedCentral

10.

Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.CrossRefPubMed

11.

Eichler J. Protein glycosylation. Curr Biol. 2019;29:R229–31.CrossRefPubMed

12.

Chen L, Ling Y, Yang H. Comprehensive Analysis of the potential prognostic value of 11 glycosylation-related genes in Head and Neck Squamous Cell Carcinoma and their correlation with PD-L1 expression and Immune Infiltration. J Oncol. 2022;2022:2786680.PubMedPubMedCentral

13.

Liao S, Lu S, Li G, Chen R. Increased maternal serum placental growth hormone variant in pregnancies complicated by otosclerosis. Clin Otolaryngol. 2019;44:757–61. https://doi.org/10.1111/coa.13385.CrossRefPubMed

14.

Constable S, Lim J-M, Vaidyanathan K, Wells L. O-GlcNAc transferase regulates transcriptional activity of human Oct4. Glycobiology. 2017;27:927–37.CrossRefPubMedPubMedCentral

15.

Gidwani K, Huhtinen K, Kekki H, van Vliet S, Hynninen J, Koivuviita N, et al. A nanoparticle-lectin immunoassay improves discrimination of serum CA125 from malignant and Benign sources. Clin Chem. 2016;62:1390–400.CrossRefPubMed

16.

Jain S, Parimelazhagan Santhi P, Vinod R, Afrin Ruma S, Huhtinen K, Pettersson K, et al. Aberrant glycosylation of α3 integrins as diagnostic markers in epithelial ovarian cancer. Clin Chim Acta. 2023;543:117323.CrossRefPubMed

17.

Vinod R, Mahran R, Routila E, Leivo J, Pettersson K, Gidwani K. Nanoparticle-aided detection of Colorectal Cancer-Associated glycoconjugates of Extracellular vesicles in human serum. Int J Mol Sci. 2021;22.

18.

Gidwani K, Kekki H, Terävä J, Soukka T, Sundfeldt K, Pettersson K. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. Mol Aspects Med. 2020;72:100831.CrossRefPubMed

19.

Terävä J, Tiainen L, Lamminmäki U, Kellokumpu-Lehtinen P-L, Pettersson K, Gidwani K. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15– 3 (CA15-3) in human plasma. PLoS ONE. 2019;14:e0219480.CrossRefPubMedPubMedCentral

20.

Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol. 1981;107:703–10. https://www.ncbi.nlm.nih.gov/pubmed/7295166.CrossRefPubMed

21.

Soukka T, Härmä H, Paukkunen J, Lövgren T. Utilization of kinetically enhanced monovalent binding affinity by immunoassays based on multivalent nanoparticle-antibody bioconjugates. Anal Chem. 2001;73:2254–60.CrossRefPubMed

22.

Søreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol. 2009;62:1–5.CrossRefPubMed

23.

Kha Q-H, Ho Q-T, Le NQK. Identifying SNARE proteins using an alignment-free Method based on Multiscan Convolutional Neural Network and PSSM profiles. J Chem Inf Model. 2022;62:4820–6.CrossRefPubMedPubMedCentral

24.

Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11. https://doi.org/10.1038/35102167.CrossRefPubMed

25.

Xu Y, Gao Z, Hu R, Wang Y, Wang Y, Su Z et al. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. J Immunother cancer. 2021;9.

26.

Chen Y-T, Chong Y-M, Cheng C-W, Ho C-L, Tsai H-W, Kasten FH, et al. Identification of novel tumor markers for oral squamous cell carcinoma using glycoproteomic analysis. Clin Chim Acta. 2013;420:45–53.CrossRefPubMed

27.

Rajpura KB, Patel PS, Chawda JG, Shah RM. Clinical significance of total and lipid bound sialic acid levels in oral pre-cancerous conditions and oral cancer. J oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2005;34:263–7.

28.

Shah M, Telang S, Raval G, Shah P, Patel PS. Serum fucosylation changes in oral cancer and oral precancerous conditions: alpha-L-fucosidase as a marker. Cancer. 2008;113:336–46.CrossRefPubMed

29.

Wong Y-L, Anand R, Yuen KM, Mustafa WMW, Abraham MT, Tay KK, et al. Identification of potential glycoprotein biomarkers in oral squamous cell carcinoma using sweet strategies. Glycoconj J. 2021;38:1–11.CrossRefPubMed

30.

Rasheduzzaman M, Murugan AVM, Zhang X, Oliveira T, Dolcetti R, Kenny L, et al. Head and neck cancer N-glycome traits are cell line and HPV status-dependent. Anal Bioanal Chem. 2022;414:8401–11.CrossRefPubMedPubMedCentral

31.

Carnielli CM, Melo de Lima Morais T, Malta de Sá Patroni F, Prado Ribeiro AC, Brandão TB, Sobroza E, et al. Comprehensive glycoprofiling of oral tumors associates N-Glycosylation with Lymph Node Metastasis and Patient Survival. Mol Cell Proteom. 2023;22:100586.CrossRef

32.

Chatterjee S, Lee LY, Kawahara R, Abrahams JL, Adamczyk B, Anugraham M, et al. Protein paucimannosylation is an enriched N-Glycosylation signature of human cancers. Proteomics. 2019;19:e1900010.CrossRefPubMed

33.

Jain S, Nadeem N, Ulfenborg B, Mäkelä M, Ruma SA, Terävä J, et al. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer. Int J cancer. 2022;151:1175–84.CrossRefPubMedPubMedCentral

34.

Kekki H, Peltola M, van Vliet S, Bangma C, van Kooyk Y, Pettersson K. Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection. Clin Biochem. 2017;50:54–61.CrossRefPubMed

35.

Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 2014;74:3238–47.CrossRefPubMed

36.

Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.CrossRefPubMed

37.

Duethorn B, Groll F, Rieger B, Drexler HCA, Brinkmann H, Kremer L, et al. Lima1 mediates the pluripotency control of membrane dynamics and cellular metabolism. Nat Commun. 2022;13:610.CrossRefPubMedPubMedCentral

38.

Clark D, Mao L. Cancer biomarker discovery: lectin-based strategies targeting glycoproteins. Dis Markers. 2012;33:1–10.CrossRefPubMedPubMedCentral

39.

McCoy JPJ, Varani J, Goldstein IJ. Enzyme-linked lectin assay (ELLA): use of alkaline phosphatase-conjugated Griffonia simplicifolia B4 isolectin for the detection of alpha-D-galactopyranosyl end groups. Anal Biochem. 1983;130:437–44.CrossRefPubMed

Title: Identification of stemness-related glycosylation changes in head and neck squamous cell carcinoma
Authors: E Routila
R Mahran
S Salminen
H Irjala
E Haapio
E Kytö
S Ventelä
K Petterson
J Routila
K Gidwani
J Leivo
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12161-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer

p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer

WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway

Investigation of ENO2 as a promising novel marker for the progression of colorectal cancer with microsatellite instability-high

Access to oncology care in Mali: a qualitative study on breast cancer

Prediction of cervical cancer screening: application of the information-motivation-behavioral skills model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer